Caffeine for apnea of prematurity: Effects on the developing brain

Atik, A, Harding, R, De Matteo, R, Kondos-Devcic, D, Cheong, J, Doyle, L and Tolcos, M 2017, 'Caffeine for apnea of prematurity: Effects on the developing brain', NeuroToxicology, vol. 58, pp. 94-102.


Document type: Journal Article
Collection: Journal Articles

Title Caffeine for apnea of prematurity: Effects on the developing brain
Author(s) Atik, A
Harding, R
De Matteo, R
Kondos-Devcic, D
Cheong, J
Doyle, L
Tolcos, M
Year 2017
Journal name NeuroToxicology
Volume number 58
Start page 94
End page 102
Total pages 9
Publisher Elsevier
Abstract Caffeine is a methylxanthine that is widely used to treat apnea of prematurity (AOP). In preterm infants, caffeine reduces the duration of respiratory support, improves survival rates and lowers the incidence of cerebral palsy and cognitive delay. There is, however, little evidence relating to the immediate and long-term effects of caffeine on brain development, especially at the cellular and molecular levels. Experimental data are conflicting, with studies showing that caffeine can have either adverse or benefical effects in the developing brain. The aim of this article is to review current understanding of how caffeine ameliorates AOP, the cellular and molecular mechanisms by which caffeine exerts its effects and the effects of caffeine on brain development. A better knowledge of the effects of caffeine on the developing brain at the cellular and/or molecular level is essential in order to understand the basis for the impact of caffeine on postnatal outcome. The studies reviewed here suggest that while caffeine has respiratory benefits for preterm infants, it may have adverse molecular and cellular effects on the developing brain; indeed a majority of experimental studies suggest that regardless of dose or duration of administration, caffeine leads to detrimental changes within the developing brain. Thus there is an urgent need to assess the impact of caffeine, at a range of doses, on the structure and function of the developing brain in preclinical studies, particularly using clinically relevant animal models. Future studies should focus on determining the maximal dose of caffeine that is safe for the preterm brain.
Subject Central Nervous System
Paediatrics
Keyword(s) Adenosine
Apnea
Brain
Caffeine
Development
Prematurity
DOI - identifier 10.1016/j.neuro.2016.11.012
Copyright notice © 2017 Elsevier B.V. All rights reserved.
ISSN 0161-813X
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 16 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Altmetric details:
Access Statistics: 7 Abstract Views  -  Detailed Statistics
Created: Thu, 21 Feb 2019, 12:10:00 EST by Catalyst Administrator
© 2014 RMIT Research Repository • Powered by Fez SoftwareContact us